Published: 8 September 2021
Author(s): Luciano Gattinoni, Mattia Busana, Luigi Camporota
Issue: October 2021
Section: Commentary

The coronavirus disease 2019 (COVID-19) causes acute respiratory failure (ARF) altering the pulmonary microvasculature with simultaneous vasoconstriction and thrombosis in ventilated areas, hyperperfusion [1] and neo-angiogenesis in gasless regions [2]. The progressive derangement of the lung vasculature and parenchyma worsens the shunt fraction and deadspace, and consequently hypoxaemia and hypercapnia.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.